Apr 25, 2007|
Pharma: The year so far...
The Indian stock markets have exhibited a volatile trend from the start of the year till the present date influenced by a host of domestic and global factors. This includes global factors such as the likely slowdown in the US market, unwinding of the yen carry trade and domestic factors such as rising inflation and CRR hikes by the Reserve Bank of India (RBI) in a bid to curb liquidity. In this scenario, the Sensex has lost marginal ground (0.1%) during the period January 2007 to April 2007. While the healthcare index lost 2% during the same period, some pharma stocks have managed to outperform both the BSE-Sensex and the BSE Healthcare index by a wide margin. In this article, we shall take a look at some of these stocks.
Pharma: Gainers and losers from Jan 2007 to Apr 2007
Biocon: Biocon has been the top performer in this four-month period with gains of 29% largely due to the strong results announced by the company both in the third and the fourth quarter of the fiscal year FY07. The two statins 'Pravastatin' and 'Simvastatin' going off patent in the US markets considerably boosted Biocon's performance for the full year. Revenues from the contract research business also played a significant role in augmenting Biocon's revenues. Biocon's subsidiary Syngene entered into a research partnership with the innovator company Bristol Myers Squibb (BMS) with the new research facility being under development. This is expected to further increase the scope of BMS's existing relationship with Syngene and is also one of the reasons for the interest generated in the stock of Biocon.
Wockhardt: Wockhardt was the second best gainer (up 19%) amongst the stocks under our research coverage due to strong results announced by the company during the fourth quarter of CY06. The company's performance has been bolstered by the acquisition of Dumex (India) with its strong brands 'Farex' and 'Protinex' in the neutraceutical space and the Irish company Pinewood Laboratories, which is expected to enhance its performance in the European region going forward. Ramp up in ANDA filings resulting in new product launches in the US market also boosted Wockhardt's performance. Overall, the company has filed 45 plus ANDAs till date with 25 plus ANDAs awaiting approval. Going forward, the company is aiming to touch the US$ 1 bn mark by FY09 (assuming that it goes in for another acquisition during this period).
Glenmark Pharma: Glenmark also caught the investors' eye during this period registering gains of 15%. The company signed an agreement with Merck for out-licensing the former's anti-diabetic molecule for milestone payments of around 190 m euros and received the first upfront payment of 25 m euros in 3QFY07. Besides this, the company also reported strong numbers for the third quarter of FY07 largely driven by strong performances by both the US and Latin American markets. Going forward, while the ramp up in the US and Latin American operations are expected to contribute to the overall performance, any adverse developments on the R&D front could impact the receipt of the milestone payments for the 2 out-licensed drugs.
Pfizer: Pfizer notched up gains of 9% during this period. The company had reported a decent set of numbers for 4QCY06 with a considerable improvement in operating margins. Having said, the overall performance in the first quarter of CY08 was a tad more subdued. With the global parent Pfizer Inc having hived off its consumer healthcare business to Johnson & Johnson, the impact of the same has yet to be reflected in the Indian operations.
Sun Pharma: Sun Pharma continued to find favour among investors notching gains of 7%. The company for the first time unveiled its innovative R&D programme with focus on both NCE (new chemical entity) and NDDS (new drug delivery system) in the respiratory and CNS field amongst others. The innovative R&D will be hived off into a separate listed company called Sun Pharma Advanced Research Company (SPARC) and the record date for the same has been fixed on April 30, 2007. Sun Pharma's aim behind this move is to focus on the relative more stable business of generics given the fact that innovative R&D is a high risk - high reward business.
From a long-term perspective, the outlook for the sector is positive with growth in generics expected to play a key role in driving revenues of domestic pharma companies. With pressures on global pharma innovators to reduce costs and spruce up margins, the CRAMS model is also expected to benefit in a big way. For MNC pharma companies, which are heavily focused on the domestic market, introduction of new products will be critical. Concerns remain with the increased competition and pricing pressures in the global generics market. For MNC pharma, 'price negotiation' for patented products will be the key factor to watch out for. The new pharmaceutical policy to be announced will also have an important bearing on both domestic and MNC companies alike. Considering all these factors, valuations of companies are important and investors need to adopt a stock-specific strategy while investing in the sector.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407